Repligen Co. (NASDAQ:RGEN) Given Consensus Rating of “Moderate Buy” by Analysts

by · The Cerbat Gem

Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $197.75.

A number of equities analysts have issued reports on the company. Stifel Nicolaus increased their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. KeyCorp lifted their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, JPMorgan Chase & Co. reduced their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd.

Read Our Latest Analysis on Repligen

Insider Activity

In other news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock valued at $5,039,532 in the last quarter. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Hedge funds have recently bought and sold shares of the stock. CWM LLC boosted its stake in Repligen by 19.9% in the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 60 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Repligen by 0.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock valued at $3,805,000 after acquiring an additional 62 shares during the period. abrdn plc increased its position in Repligen by 1.4% during the fourth quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after acquiring an additional 71 shares during the period. Commerce Bank raised its stake in Repligen by 4.5% in the 4th quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 72 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its holdings in Repligen by 15.1% in the 4th quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 85 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Price Performance

Shares of RGEN opened at $166.81 on Tuesday. The stock has a 50 day simple moving average of $178.07 and a 200 day simple moving average of $174.90. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The firm has a market capitalization of $9.32 billion, a PE ratio of 667.27, a P/E/G ratio of 5.51 and a beta of 1.03.

Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. During the same quarter last year, the company earned $0.64 EPS. The firm’s quarterly revenue was down 17.1% compared to the same quarter last year. Sell-side analysts predict that Repligen will post 1.46 EPS for the current fiscal year.

About Repligen

(Get Free Report

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Articles